Macugen pegaptanib: Phase III data

In the double-blind, placebo-controlled, dose-ranging, international Phase III VISION trial in 1,186 patients, 70%

Read the full 143 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE